1
|
Ray PK, Shabana K, Salahuddin, Kumar R. Synthetic Strategies of Thiazolidine-2,4-dione Derivatives for the Development of New Anti-diabetic Agents: Compressive Review. Curr Top Med Chem 2024; 24:885-928. [PMID: 38500288 DOI: 10.2174/0115680266284283240304071648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 02/06/2024] [Accepted: 02/13/2024] [Indexed: 03/20/2024]
Abstract
BACKGROUND Thiazolidine-2,4-dione (2,4-TZD) is a flexible pharmacophore and a privileged platform and contains a five-membered ring with a 2-oxygen atom with double bond 2,4- position and one nitrogen atom as well as sulphur containing in the heterocyclic compound. A famous electron-rich nitrogen transporter combines invigorating electronic properties with the prospective for elemental applications. Thiazolidine-2,4-dione analogues have been synthesized using a variety of methods, all of which have shown to have a strong biological effect. OBJECTIVES The study of the biological activity of Thiazolidine-2,4-dione derivatives has been a fascinating field of pharmaceutical chemistry and has many purposes. This derivative described in the literature between 1995 to 2023 was the focus of this study. Thiazolidine-2,4-diones have been discussed in terms of their introduction, general method, synthetic scheme and antidiabetic significance in the current review. CONCLUSION Thiazolidine-2,4-diones are well-known heterocyclic compounds. The synthesis of Thiazolidine-2,4-diones has been described using a variety of methods. Antidiabetic activity has been discovered in several Thiazolidine-2,4-dione derivatives, which enhance further research. The use of Thiazolidine-2,4-diones to treat antidiabetics has piqued researchers' interest in learning more about thiazolidine-2,4-diones.
Collapse
Affiliation(s)
- Pushkar Kumar Ray
- Department of Pharmacy, Harlal Institute of Management and Technology (HIMT), Plot no-8, Knowledge Park-1, Greater Noida, Uttar Pradesh, 201310, India
| | - Km Shabana
- Department of Pharmacy, Harlal Institute of Management and Technology (HIMT), Plot no-8, Knowledge Park-1, Greater Noida, Uttar Pradesh, 201310, India
| | - Salahuddin
- Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, 201306, India
| | - Rajnish Kumar
- Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, 201306, India
| |
Collapse
|
2
|
Levshin IB, Simonov AY, Lavrenov SN, Panov AA, Grammatikova NE, Alexandrov AA, Ghazy ESMO, Savin NA, Gorelkin PV, Erofeev AS, Polshakov VI. Antifungal Thiazolidines: Synthesis and Biological Evaluation of Mycosidine Congeners. Pharmaceuticals (Basel) 2022; 15:ph15050563. [PMID: 35631390 PMCID: PMC9145892 DOI: 10.3390/ph15050563] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 04/28/2022] [Accepted: 04/29/2022] [Indexed: 02/01/2023] Open
Abstract
Novel derivatives of Mycosidine (3,5-substituted thiazolidine-2,4-diones) are synthesized by Knoevenagel condensation and reactions of thiazolidines with chloroformates or halo-acetic acid esters. Furthermore, 5-Arylidene-2,4-thiazolidinediones and their 2-thioxo analogs containing halogen and hydroxy groups or di(benzyloxy) substituents in 5-benzylidene moiety are tested for antifungal activity in vitro. Some of the synthesized compounds exhibit high antifungal activity, both fungistatic and fungicidal, and lead to morphological changes in the Candida yeast cell wall. Based on the use of limited proteomic screening and toxicity analysis in mutants, we show that Mycosidine activity is associated with glucose transport. This suggests that this first-in-class antifungal drug has a novel mechanism of action that deserves further study.
Collapse
Affiliation(s)
- Igor B. Levshin
- Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia; (I.B.L.); (A.Y.S.); (S.N.L.); (N.E.G.)
| | - Alexander Y. Simonov
- Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia; (I.B.L.); (A.Y.S.); (S.N.L.); (N.E.G.)
| | - Sergey N. Lavrenov
- Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia; (I.B.L.); (A.Y.S.); (S.N.L.); (N.E.G.)
| | - Alexey A. Panov
- Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia; (I.B.L.); (A.Y.S.); (S.N.L.); (N.E.G.)
- Correspondence:
| | - Natalia E. Grammatikova
- Gause Institute of New Antibiotics, 11 B. Pirogovskaya Street, 119021 Moscow, Russia; (I.B.L.); (A.Y.S.); (S.N.L.); (N.E.G.)
| | - Alexander A. Alexandrov
- Bach Institute of Biochemistry, Federal Research Center of Biotechnology of the RAS, 119071 Moscow, Russia; (A.A.A.); (E.S.M.O.G.)
| | - Eslam S. M. O. Ghazy
- Bach Institute of Biochemistry, Federal Research Center of Biotechnology of the RAS, 119071 Moscow, Russia; (A.A.A.); (E.S.M.O.G.)
- Institute of Biochemical Technology and Nanotechnology, Peoples’ Friendship University of Russia (RUDN), 6 Miklukho-Maklaya Street, 117198 Moscow, Russia
- Department of Microbiology, Faculty of Pharmacy, Tanta University, Tanta 31111, Egypt
| | - Nikita A. Savin
- Research Laboratory of Biophysics, National University of Science and Technology “MISiS”, 4 Leninsky Ave., 119049 Moscow, Russia; (N.A.S.); (P.V.G.); (A.S.E.)
| | - Peter V. Gorelkin
- Research Laboratory of Biophysics, National University of Science and Technology “MISiS”, 4 Leninsky Ave., 119049 Moscow, Russia; (N.A.S.); (P.V.G.); (A.S.E.)
| | - Alexander S. Erofeev
- Research Laboratory of Biophysics, National University of Science and Technology “MISiS”, 4 Leninsky Ave., 119049 Moscow, Russia; (N.A.S.); (P.V.G.); (A.S.E.)
| | - Vladimir I. Polshakov
- Faculty of Fundamental Medicine, Lomonosov Moscow State University, 27/1 Lomonosovsky Ave., 119991 Moscow, Russia;
| |
Collapse
|
3
|
Habibi-Khorassani SM, Shahraki M, Talaiefar S, Ghodsi F. Ionic strength effect on the kinetics and mechanism of N-vinyl compound formation in the presence of heterocyclic biological base: empirical and theoretical approaches. Mol Phys 2021. [DOI: 10.1080/00268976.2021.1957171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
| | - Mehdi Shahraki
- Department of Chemistry, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran
| | - Sadegh Talaiefar
- Department of Chemistry, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran
| | - Fatemeh Ghodsi
- Department of Chemistry, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran
| |
Collapse
|
4
|
Li P, Patel R, Guo J, Vouri SM, Shi L, Fonseca V, Shao H. The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018. Curr Med Res Opin 2021; 37:1875-1880. [PMID: 34429001 DOI: 10.1080/03007995.2021.1971181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND The difference between the costs of the newer and older glucose-lowering drugs (GLMs) has been steadily increasing since 2010. In 2018, newer drugs cost 8-12 times more than older drugs (except for insulin). This study aimed to understand how the cost change influenced the cost-effectiveness of the newer GLMs. METHODS Based on our previous literature review on US-based cost-effectiveness studies comparing newer (i.e. dipeptidyl peptidase-4 inhibitors (DPP4), glucagon-like peptide 1 receptor agonists (GLP1-RA), and sodium-glucose transport protein 2 inhibitors) with older GLMs, we identified 12 studies that reported the cost-effectiveness of newer drugs based on drug costs estimated before 2010. We updated the corresponding cost-effectiveness of each study by replacing the old cost estimates with 2018 estimates from the 2018 IBM MarketScan Commercial Claims Databases. The time window and willingness to pay threshold were consistent with the original studies. RESULTS Only 8% of the original studies suggested that the older drugs were cost-effective. However, 58% of studies were in favor of the older drugs after the cost update. Among the four studies comparing newer drugs with thiazolidinediones, all the original results favored newer drugs. However, all studies suggested thiazolidinedione to be cost-effective in the updated analysis. For the four studies comparing newer drugs with sulfonylureas, two studies suggested the sulfonylureas to be cost-effective after the cost update. All four studies suggested newer drugs to be cost-effective when compared with insulin in the original study. Only 1 flipped its conclusion when 2018 costs were used. Our sensitivity analysis shows that our results are robust under a 30% rebate. CONCLUSION Significant changes in the cost of GLMs have impacted the economic value of different GLM classes substantially. More cost-effectiveness analyses are warranted to support the drug choice in T2DM management.
Collapse
Affiliation(s)
- Piaopiao Li
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - Rahul Patel
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - Jingchuan Guo
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
- Center for Drug Evaluation and Safety, University of Florida College of Pharmacy, Gainesville, FL, USA
| | - Scott M Vouri
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - Lizheng Shi
- Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA
| | - Vivian Fonseca
- Department of Medicine and Pharmacology, School of Medicine, Tulane University, New Orleans, LA, USA
| | - Hui Shao
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA
| |
Collapse
|
5
|
Horgan C, O' Sullivan TP. Recent Developments in the Practical Application of Novel Carboxylic Acid Bioisosteres. Curr Med Chem 2021; 29:2203-2234. [PMID: 34420501 DOI: 10.2174/0929867328666210820112126] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 07/10/2021] [Accepted: 07/23/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND The carboxylic acid is an important functional group which features in the pharmacophore of some 450 drugs. Unfortunately, some carboxylic acid-containing drugs have been withdrawn from market due to unforeseen toxicity issues. Other issues associated with the carboxylate moiety include reduced metabolic stability or limited passive diffusion across biological membranes. Medicinal chemists often turn to bioisosteres to circumvent such obstacles. OBJECTIVE The aim of this review is to provide a summary of the various applications of novel carboxylic acid bioisosteres which have appeared in the literature since 2013. RESULTS We have summarised the most recent developments in carboxylic acid bioisosterism. In particular, we focus on the changes in bioactivity, selectivity or physiochemical properties brought about by these substitutions, as well as the advantages and disadvantages of each isostere. CONCLUSION The topics discussed herein highlight the continued interest in carboxylate bioisosteres. The development of novel carboxylic acid substitutes which display improved pharmacological profiles is testament to the innovation and creativity required to overcome the challenges faced in modern drug design.
Collapse
Affiliation(s)
- Conor Horgan
- School of Chemistry, University College Cork, Cork. Ireland
| | | |
Collapse
|
6
|
Nyaki HY, Mahmoodi NO. Synthesis and characterization of derivatives including thiazolidine-2,4-dione/1-H- imidazole and evaluation of antimicrobial, antioxidant, and cytotoxic properties of new synthetic heterocyclic compounds. RESEARCH ON CHEMICAL INTERMEDIATES 2021. [DOI: 10.1007/s11164-021-04525-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
7
|
Croppi G, Zhou Y, Yang R, Bian Y, Zhao M, Hu Y, Ruan BH, Yu J, Wu F. Discovery of an Inhibitor for Bacterial 3-Mercaptopyruvate Sulfurtransferase that Synergistically Controls Bacterial Survival. Cell Chem Biol 2020; 27:1483-1499.e9. [DOI: 10.1016/j.chembiol.2020.10.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2019] [Revised: 08/12/2020] [Accepted: 10/22/2020] [Indexed: 12/19/2022]
|
8
|
Haroun M. In Silico Design, Synthesis and Evaluation of Novel Series of Benzothiazole- Based Pyrazolidinediones as Potent Hypoglycemic Agents. Med Chem 2020; 16:812-825. [DOI: 10.2174/1573406416666191227113716] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2019] [Revised: 09/26/2019] [Accepted: 10/29/2019] [Indexed: 12/30/2022]
Abstract
Background:
The discovery of novel ligand binding domain (LBD) of peroxisome proliferator-
activated receptor γ (PPARγ) has recently attracted attention to few research groups in order
to develop more potent and safer antidiabetic agents.
Objective:
This study is focused on docking-based design and synthesis of novel compounds combining
benzothiazole and pyrazolidinedione scaffold as potential antidiabetic agents.
Methods:
Several benzothiazole-pyrazolidinedione hybrids were synthesized and tested for their in
vivo anti-hyperglycemic activity. Interactions profile of title compounds against PPARγ was examined
through molecular modelling approach.
Results:
All tested compounds exhibited anti-hyperglycemic activity similar or superior to the reference
drug Rosiglitazone. Introducing chlorine atom and alkyl group at position-6 and -5 respectively
on benzothiazole core resulted in enhancing the anti-hyperglycemic effect. Docking study
revealed that such groups demonstrated favorable hydrophobic interactions with novel LBD Ω-
pocket of PPARγ protein.
Conclusion:
Among the tested compounds, N-(6-chloro-5-methylbenzo[d]thiazol-2-yl-4-(4((3,5-
dioxopyrazolidin-4-ylidene)methyl)phenoxy)butanamide 5b was found to be the most potent compound
and provided valuable insights to further develop novel hybrids as anti-hyperglycemic
agents.
Collapse
Affiliation(s)
- Michelyne Haroun
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia
| |
Collapse
|
9
|
Kumari L, Salahuddin, Mazumder A, Pandey D, Yar MS, Kumar R, Mazumder R, Sarafroz M, Ahsan MJ, Kumar V, Gupta S. Synthesis and Biological Potentials of Quinoline Analogues: A Review of Literature. MINI-REV ORG CHEM 2019. [DOI: 10.2174/1570193x16666190213105146] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Heterocyclic compounds are well known for their different biological activity. The heterocyclic analogs are the building blocks for synthesis of the pharmaceutical active compounds in the organic chemistry. These derivatives show various type of biological activity like anticancer, antiinflammatory, anti-microbial, anti-convulsant, anti-malarial, anti-hypertensive, etc. From the last decade research showed that the quinoline analogs plays a vital role in the development of newer medicinal active compounds for treating various type of disease. Quinoline reported for their antiviral, anticancer, anti-microbial and anti-inflammatory activity. This review will summarize the various synthetic approaches for synthesis of quinoline derivatives and to check their biological activity. Derivatives of quinoline moiety plays very important role in the development of various types of newer drugs and it can be used as lead compounds for future investigation in the field of drug discovery process.
Collapse
Affiliation(s)
- Leena Kumari
- Noida Institute of Engineering and Technology (Pharmacy Institute), Plot No. 19, Knowledge Park-2, Greater Noida, Utter Pardesh-201306, India
| | - Salahuddin
- Noida Institute of Engineering and Technology (Pharmacy Institute), Plot No. 19, Knowledge Park-2, Greater Noida, Utter Pardesh-201306, India
| | - Avijit Mazumder
- Noida Institute of Engineering and Technology (Pharmacy Institute), Plot No. 19, Knowledge Park-2, Greater Noida, Utter Pardesh-201306, India
| | - Daman Pandey
- Noida Institute of Engineering and Technology (Pharmacy Institute), Plot No. 19, Knowledge Park-2, Greater Noida, Utter Pardesh-201306, India
| | - Mohammad Shahar Yar
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard University, Hamdard Nagar, New Delhi-110062, India
| | - Rajnish Kumar
- Noida Institute of Engineering and Technology (Pharmacy Institute), Plot No. 19, Knowledge Park-2, Greater Noida, Utter Pardesh-201306, India
| | - Rupa Mazumder
- Noida Institute of Engineering and Technology (Pharmacy Institute), Plot No. 19, Knowledge Park-2, Greater Noida, Utter Pardesh-201306, India
| | - Mohammad Sarafroz
- Department of Pharmaceutical Chemistry, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, City Dammam, Saudi Arabia
| | - Mohamed Jawed Ahsan
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia
| | - Vivek Kumar
- Noida Institute of Engineering and Technology (Pharmacy Institute), Plot No. 19, Knowledge Park-2, Greater Noida, Utter Pardesh-201306, India
| | - Sushma Gupta
- Noida Institute of Engineering and Technology (Pharmacy Institute), Plot No. 19, Knowledge Park-2, Greater Noida, Utter Pardesh-201306, India
| |
Collapse
|
10
|
Jena S, Mishra B, Yadav A, Desai P. Challenges in diabetology research in India. Diabetes Metab Syndr 2018; 12:349-355. [PMID: 29307575 DOI: 10.1016/j.dsx.2017.12.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Accepted: 12/19/2017] [Indexed: 11/30/2022]
Abstract
BACKGROUND Diabetes emerges out to be a major epidemic in recent years that engulfs both developed and developing countries across the globe. India, a country witnessing rapid socioeconomic progress and urbanization carries a considerable share of the global diabetes burden. There has been an incongruity between disease burden and the technical capacity to make use of existing knowledge or to generate new knowledge to combat diabetes in India. AIM This paper examines the role of different actors, organizations & institutions in shaping diabetology research in India using arrays of scientific indicators such as research output (publications and patents), research finance and role of policy-making bodies. This paper also identifies research gaps and challenges pertinent to this sector. METHODOLOGY A combination of three methods patent data analysis, publication data analysis and primary survey corroborated with secondary data to obtain desire objectives. We made an in-depth study of the patent and publication data (2000-2016) to know the research output and direction of Indian actors, institutions and organizations in the area of diabetes research. RESULTS This paper identifies some key structural barriers and institutional challenges pertinent to diabetology research in India that will help in canvassing and formulating science, technology and policy guidelines for diabetology research in India CONCLUSION: Multilevel intervention requires bridging the gap between knowledge and action hence policy-making should align to balance resources with innovation capabilities.
Collapse
Affiliation(s)
- Swarup Jena
- Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delhi, India.
| | - Brijesh Mishra
- Centre for Diabetes Endocrinology & Metabolism, University College of Medical Sciences & Guru Teg Bahadur Hospital, Delhi, India
| | - Anamika Yadav
- Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delhi, India
| | - Pranav Desai
- Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delhi, India
| |
Collapse
|
11
|
Giampietro L, Ammazzalorso A, Bruno I, Carradori S, De Filippis B, Fantacuzzi M, Giancristofaro A, Maccallini C, Amoroso R. Synthesis of Naphthyl-, Quinolin- and Anthracenyl Analogues of Clofibric Acid as PPARαAgonists. Chem Biol Drug Des 2015; 87:467-71. [DOI: 10.1111/cbdd.12677] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2015] [Revised: 08/22/2015] [Accepted: 09/14/2015] [Indexed: 11/28/2022]
Affiliation(s)
- Letizia Giampietro
- Dipartimento di Farmacia; Università “G. d'Annunzio” di Chieti; via dei Vestini 66100 Chieti Italy
| | - Alessandra Ammazzalorso
- Dipartimento di Farmacia; Università “G. d'Annunzio” di Chieti; via dei Vestini 66100 Chieti Italy
| | - Isabella Bruno
- Dipartimento di Farmacia; Università “G. d'Annunzio” di Chieti; via dei Vestini 66100 Chieti Italy
| | - Simone Carradori
- Dipartimento di Farmacia; Università “G. d'Annunzio” di Chieti; via dei Vestini 66100 Chieti Italy
| | - Barbara De Filippis
- Dipartimento di Farmacia; Università “G. d'Annunzio” di Chieti; via dei Vestini 66100 Chieti Italy
| | - Marialuigia Fantacuzzi
- Dipartimento di Farmacia; Università “G. d'Annunzio” di Chieti; via dei Vestini 66100 Chieti Italy
| | - Antonella Giancristofaro
- Dipartimento di Farmacia; Università “G. d'Annunzio” di Chieti; via dei Vestini 66100 Chieti Italy
| | - Cristina Maccallini
- Dipartimento di Farmacia; Università “G. d'Annunzio” di Chieti; via dei Vestini 66100 Chieti Italy
| | - Rosa Amoroso
- Dipartimento di Farmacia; Università “G. d'Annunzio” di Chieti; via dei Vestini 66100 Chieti Italy
| |
Collapse
|